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Introduction
The practice of performing systematic biopsies in all men with raised PSA levels causes unacceptable rates of over diagnosis and overtreatment of Gleason score 6 prostate cancer [1] . Gleason score 6 cancers are currently considered indolent with a negligible capacity to metastasise [1, 2] . Moreover, standard TRUS-guided biopsy often misses clinically significant disease, especially in the anterior and central parts of the prostate [3] [4] [5] . Multiparametric MRI (mpMRI) of the prostate followed by targeted biopsies is therefore increasingly used to enhance the detection of Gleason score ≥7 prostate cancer and to reduce the detection of clinically insignificant Gleason score 6 cancer. A negative mpMRI has a high negative predictive value (NPV) for the detection of Gleason score ≥7 cancer on biopsy [6] [7] [8] [9] . Guidelines currently recommend mpMRI with targeted biopsies, especially for men with previous negative biopsies and for men considered for active surveillance (AS) [10] [11] [12] . Nevertheless, mpMRI may miss Gleason score 7 cancer in up to 24% of patients, when a radical prostatectomy specimen is used as the reference method [13, 14] . There is thus a need for additional predictors for men with a negative or equivocal mpMRI to select those who may not need to undergo biopsy.
One such predictor could be PSA density (PSAD). Prostatectomy studies have shown that PSAD is strongly associated with the presence of Gleason score ≥7 cancer [15] [16] [17] [18] . A recent study showed that PSAD calculated by MR/ TRUS fusion software is strongly associated with the detection of Gleason score ≥7 cancer in men with or without previous biopsies, but no threshold values for PSAD were evaluated [19] . Two other studies both reported no Gleason score ≥7 cancer in targeted biopsies from equivocal mpMRI lesions in men with no previous biopsies, but there were only 18 and six patients in this group [20, 21] . We used our large database on transperineal MR/US fusion-guided prostate biopsy to define clinically useful PSAD threshold values, based on positive (PPV) and negative (NPV) predictive values with CIs, under which men with previous biopsies may not need repeated biopsies in the absence of MRI findings suspicious for cancer.
Patients and Methods

Standards of Reporting
The Standards of Reporting for MRI-targeted Biopsy Studies (START) were used to describe the study population, the conduct and reporting of the MRI, and the conduct of the biopsy [22] .
Study Population
From January 2013 to December 2015, 712 men underwent transperineal prostate biopsies at our institution. This retrospective study was part of a service evaluation of transperineal prostate biopsies with the need for informed consent for data analysis waived by the Local Ethics Committee. In all, 146 patients without previous biopsies and four with previous treatment for prostate cancer were excluded from the analysis. Patients on AS for Gleason score 7 cancer (22) were also excluded, as their disease already met our outcome measure. Furthermore, we excluded 15 patients on AS who were diagnosed with Gleason score 6 cancer before 2010, to ensure that the diagnostic Gleason grading for all included patients was done according to the 2005 International Society of Urological Pathology (ISUP) criteria [23] , and 15 patients due to insufficient data recording. The final study cohort thus comprised 514 men who had biopsies between January 2013 and December 2015, of whom 351 men had previous negative TRUS biopsies and 163 were on AS for Gleason score 6 cancer. The patients' clinical characteristics are shown in Table 1 .
MRI
Patients underwent prostate MRI on a 1.5-T MR450 or 3.0-T Discovery MR750 HDx (GE Healthcare, Waukesha, USA) with an 8-16 channel surface phased-array coil. Axial fast spin-echo T1-weighted images of the pelvis, along with T2-weighted (T2WI) fast-recovery fast spin-echo images of the prostate were acquired in the axial (slice thickness 3 mm; gap 0-1 mm), sagittal, and coronal planes. Axial diffusionweighted imaging (DWI) was performed using a spin-echo echo-planar imaging pulse sequence with a slice thickness of 
Image Analysis
MRI images were prospectively reported by one of two subspecialised uroradiologists with >5 years' experience of reading prostate MRI. T2WI and DWI sequences were evaluated using a Likert scale, based on the Prostate Imaging Reporting and Data System (PI-RADS) structured scoring criteria developed by the European Society of Urogenital Radiology (ESUR) [24] , together with clinical information. The final score was defined by combining all scores for T2WI and DWI sequences as is now recommended in PI-RADS version 2 [25] : 1 = cancer highly unlikely, 2 = cancer unlikely, 3 = equivocal for cancer, 4 = cancer likely, 5 = cancer highly likely. The contours of Likert 3-5 lesions were drawn on the Biopsee TM MRI-TRUS fusion-biopsy platform (Medcom, Darmstadt, Germany). The prostate volume was measured both by MRI-based prolate ellipsoid formula (three diameters measured directly on the MRI images, volume = length 9 width 9 height 9 p/6) and by MRI threedimensional (3D) reconstruction volumetry (automatically calculated by the MRI/US-fusion software, using the manually outlined cross-section areas).
Biopsy
The Biopsee TM MRI/TRUS fusion-biopsy system version 1 or 2 (Medcom, Darmstadt, Germany) was used for all biopsies. All patients had 24 systematic biopsies taken according to the Ginsburg protocol, using a spring-loaded biopsy gun with an 18-G needle [9, 26] . Two biopsy cores were sampled from each of 12 sectors, starting with the anterior sectors. In patients with Likert 3-5 MRI lesions, two biopsy cores were taken from each lesion before the systematic biopsies. All procedures were done by one of three urologists with several years' experience of transperineal biopsy using the Biopsee MRI/TRUS fusion-biopsy system.
Histopathology
All biopsies were graded according to the ISUP 2005 recommendations by a specialist uropathologist and reviewed by another uropathologist before a multidisciplinary team meeting [23] . In case of discrepancy between these two pathologists in the grading of a specimen, a third uropathologist was consulted and a consensus was reached. The consensus agreement on the final Gleason score was used for this study.
Statistics
A multivariable model with PSAD, MRI findings and previous biopsy results showed no difference in the influence of PSAD on the PPV and NPV values in men with Gleason score 6 cancer on previous biopsy compared with men with previous benign biopsies (reference): odds ratio 0.92 (95% CI: 0.63-1.34). Moreover, the clinical characteristics of the two groups were almost identical ( Table 1) . We therefore merged the two groups and analysed them together.
The differences in the calculated prostate volumes, as measured by MRI-based prolate ellipsoid formula compared with MRI 3D-reconstruction volumetry, were analysed as the median difference and interquartile range (IQR). There was a negligible difference between the two methods and we chose to use the prolate ellipsoid formula calculated volumes for further analysis of PSAD because this is available when the decision is made whether to proceed with a biopsy or not. PPVs and NPVs with 95% CIs were first calculated for PSAD of ≤0.1, 0.11-0.2, and >0.2 ng/ mL/mL. When we found that the results were almost identical for PSADs of ≤0.1 and 0.11-0.2 ng/mL/mL, when applied to Likert 1-3 MRIs, we added analyses with these two groups merged into a single PSAD of <0.2 ng/mL/mL group. The chi-square test with test for linear trend was used to compare differences in proportions.
Results
Overall Influence of PSAD on Cancer Detection
Gleason score ≥7 cancer was detected in 31% of all men, in 16% (95% CI: 11-21%) of men with a PSAD of ≤0.1 ng/ mL/mL, in 30% (95% CI: 23-37%) with a PSAD of 0.11-0.2 ng/mL/mL, and 54% (95% CI: 47-62%) with a PSAD of >0.2 ng/mL/mL (P < 0.001 for trend). Gleason score ≥4 + 3 cancer was detected in 13% of all men, in 4% (95% CI: 1-7%) of men with a PSAD of ≤0.1 ng/mL/mL, in 13% (95% CI: 8-18%) with a PSAD of 0.11-0.2 ng/mL/mL, and in 26% (95% CI: 19-33%) with a PSAD of >0.2 ng/mL/mL(P < 0.001 for trend).
Influence of PSAD on NPV of Negative mpMRI
The NPV for Gleason score ≥7 of negative (Likert 1-2) MRIs was 0.91 (95% CI: 0.86-0.96) with a PSAD of ≤0.2 ng/mL/mL and 0.71 (95% CI: 0.55-0.87) with a PSAD of >0.2 ng/mL/ mL (P = 0.003; Table 2 ). NPVs with a PSAD of ≤0.1 and 0.11-0.2 ng/mL/mL were both 0.91 (P = 0.98). Of 13 (9%) Gleason score ≥7 cancers in 142 men with a negative mpMRI and a PSAD of ≤0.2 ng/mL/mL, nine (6%) were Gleason score 3 + 4, one (0.7%) was Gleason score 4 + 3, and three (1.4%) were Gleason score 8-10 cancers.
Influence of PSAD on PPV of Equivocal mpMRI
The PPV for Gleason score ≥7 of equivocal (Likert 3) MRIs was 0.09 (95% CI: 0.03-0.15) with a PSAD of ≤0.2 ng/mL/ mL and 0.44 (95% CI: 0.25-0.63) with a PSAD of >0.2 ng/ mL/mL (P = 0.003; Table 3 ). The PPVs with a PSAD ≤0.1 and 0.11-0.2 ng/mL/mL were similar (0.10 vs 0.09; P = 0.98). Of nine (9%) Gleason score ≥7 cancers in 96 men with an equivocal mpMRI and a PSAD of ≤0.2 ng/mL/ mL, six (6%) were Gleason score 3 + 4, one (1%) was Gleason score 4 + 3, and two (2%) were Gleason score 8-10 cancers. 
Influence of PSAD on PPV of mpMRIs Suspicious for Cancer
The PPV for Gleason score ≥7 with suspicious (Likert 4-5) MRIs was 0.30 (95% CI: 0.18-0.42) with a PSAD of ≤0.1 ng/mL/mL, 0.60 (95% CI: 0.49-0.71) with a PSAD of 0.11-0.2 ng/mL/mL, and 0.66 (95% CI: 0.56-0.76) with a PSAD of >0.2 ng/mL/mL (P < 0.001 for trend Table 4 ). Gleason score ≥4 + 3 cancer was more common among those with higher PSADs (P < 0.001 for trend): 7% of 60 men with a PSAD of ≤0.1 ng/mL/mL, 28% of 78 men with a PSAD of 0.11-0.2 ng/mL/mL, and 35% of 82 men with a PSAD of >0.2 ng/mL/mL.
Comparison of MRI based Prolate Ellipsoid and 3D-Prostate Volume Measurements
Volume measurements did not significantly differ between MRI-based prolate formula calculation and 3D-volume reconstruction, with median (IQR) volume of 59 (38-81) mL for the prolate formula calculation and 60 (40-81) mL for 3D-volume reconstruction. The 3D-volume was larger with a median (IQR) of 2 (-5 to 7) mL more than the prolate ellipsoid formula. The median PSAD was 0.13 ng/mL/mL both with the prolate formula calculation and with 3D-volume reconstruction.
Discussion
Our present study shows that in a repeat biopsy setting, a negative mpMRI (Likert 1-2) is associated with a NPV of 91% (95% CI: 86-97%) to detect Gleason score ≥7 prostate cancer in men with a PSAD of ≤0.2 ng/mL/mL, with no difference between PSADs of <0.1 and 0.11-0.2 ng/mL/mL. PSAD also strongly influenced the PPVs for equivocal and suspicious (Likert/PI-RADS 3-5) mpMRIs. The PPV of a Likert 3 mpMRI for detecting Gleason score ≥7 cancer was as low as 9% in men with a PSAD of ≤0.2 ng/mL/mL, again with no difference between PSADs of ≤0.1 and 0.11-0.2 ng/mL/mL. Conversely, the PPV was high in men with a high PSAD and a negative mpMRI, as well as in men with suspicious cancer on mpMRI and a low PSAD.
Our present findings suggest that men with a PSAD of ≤0.2 ng/mL/mL and a negative or equivocal mpMRI (Likert/ PI-RADS 3) may be spared an immediate repeat prostate biopsy. In our present study population, this group of patients constituted almost half of all men and~80% of the men with a Likert 1-2 or a Likert 3 mpMRI. Whether a 10% risk of Gleason score ≥7 cancer is acceptable for PSA surveillance without an immediate repeat biopsy is of course debatable, and the decision should be individualised. Most urologists would, however, not recommend a prostate biopsy for men with a PSA level of 2-3 ng/mL and a clinically benign prostate, despite a similar prevalence of Gleason score ≥7 cancer.* Three recent studies investigated the influence of PSAD on Gleason score ≥7 cancer detection on targeted and systematic biopsy based on mpMRI findings [19] [20] [21] . Abdi et al. [20] reported that among men with no previous prostate biopsy, 34% with PSAD of >0.15 ng/mL/mL and 16% with a PSAD of <0.15 ng/mL/mL had Gleason score ≥7 cancer on MR/USfusion targeted plus systematic 8-12 core transrectal biopsies. None of the 18 men with a PI-RADS 3 lesion and a PSAD of <0.15 ng/mL/mL had cancer on biopsy. They did not report on NPVs of PI-RADS 1-2 MRIs. Filson et al. [19] studied men both with and without previous biopsies, including men on AS for Gleason score 6 cancer. They found that PSAD was significantly associated with detecting Gleason score ≥7 cancer on MR/US-fusion targeted plus systematic 8-12 core transrectal biopsies, but they did not report any NPVs or PPVs. Washino et al. [21] reported similar findings in men with no previous biopsy, with cognitively targeted plus 14-core systematic transperineal biopsies as the reference method. No Gleason score ≥7 cancer was detected in the men with a PSAD of <0.15 ng/mL/mL who had a PI-RADS 1-2 MRI (38 men) or a PI-RADS 3 lesion (six men). Our present study adds to these three studies by providing NPVs and PPVs with reasonably narrow CIs for men with previous biopsies, stratified by PSAD and MRI findings. Moreover, the extensive biopsy protocol (targeted and systematic 24-core image-fusion guided transperineal biopsy) used in our present study is less likely to miss Gleason score ≥7 cancer [3, 30] .
PSAD influenced the PPV also for positive mpMRIs (Likert/ PI-RADS 4-5), but the risk of Gleason score ≥7 prostate cancer was high enough to warrant a biopsy also in men with a low PSAD. An MRI reading that is incongruent with the PSAD (positive MRI with low PSAD or negative MRI with PSAD of >0.2 ng/mL/mL) could be a trigger for a second opinion on the interpretation of the imaging by a subspecialised prostate radiologist. Our present results are in agreement with those of Washino et al. [21] , who reported significant cancer in two of seven men with a PSAD of <0.15 ng/mL/mL and in 89% of 110 men with a PSAD of ≥0.15 ng/mL/mL in the presence of PI-RADS 4-5 lesions.
In addition to assessing the interaction between PSAD and cancer detection, we established that using three prostate diameters for the prolate formula calculation of PSAD is *In the placebo arm of the Prostate Cancer Prevention Trial (PCPT), 5% of men in with a PSA of 2-3 ng/mL had Gleason score ≥7 cancer on sextant biopsy [27] . Gleason grading in the PCPT was made before the ISUP conference revised the grading criteria in 2005 [23] , so with current grading the proportion of Gleason score 7 cancer would have been considerably higher than 5% [28] . Moreover, the transrectal sextant biopsy used in the PCPT has a low sensitivity [29] , so more Gleason score 7 cancer would have been detected with a 24-core transperineal biopsy.
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Limitations of the present study include its retrospective design and that no calculation of statistical power was made in advance. We also had no information on if PSA velocity or other clinical factors were used to select patients for repeat biopsy. Large prospective multicentre studies are needed to validate our present results, before guidelines can incorporate a recommendation for surveillance rather than targeted biopsies for men with a low PSAD and an equivocal MRI. Moreover, our present results were obtained at a highvolume, tertiary care centre with a long experience of prostate mpMRI and image-guided targeted biopsies, optimised MRI protocols, and subspecialist prostate radiologists. Urologists need to be aware of the experience of the reporting radiologist when making clinical decisions based on mpMRI results. Inexperienced radiologists might overcall equivocal lesions and miss suspicious lesions, whereas experienced radiologists may help limit the number of equivocal and suspicious lesions to target with biopsies and reduce the risk of missing lesions with significant cancer [31, 32] .
Conclusion
In a repeat biopsy setting, a PSAD of ≤0.2 ng/mL/mL is associated with a low detection of Gleason score ≥7 prostate cancer, not only in men with negative mpMRI, but also in men with equivocal imaging. Surveillance, rather than repeat biopsy, may be appropriate for these men. Conversely, biopsies are indicated in men with a high PSAD, even if an mpMRI shows no suspicious lesion, and in men with an MRI suspicious for cancer, even if the PSAD is low.
